XML 16 R6.htm IDEA: XBRL DOCUMENT v3.20.2
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2020
Mar. 31, 2020
Jun. 30, 2019
Mar. 31, 2019
Jun. 30, 2020
Jun. 30, 2019
Dec. 31, 2019
Cash flows used in operating activities:              
Net loss $ (1,839) $ (1,087) $ (9,147) $ (3,150) $ (2,926) $ (12,297)  
Adjustments to reconcile net loss to net cash used in operating activities:              
Depreciation and amortization         188 617  
Amortization of deferred financing costs and debt discount         275 257  
In process research and development acquired from NanoTx Therapeutics         781 0  
Noncash lease expenses         9 39  
Change in fair value of warrants (756)   (282)   (2,423) (492)  
Share-based compensation expense         55 77  
Loss on sale of business         0 6,508  
Increases (decreases) in cash caused by changes in operating assets and liabilities:              
Accounts receivable         218 (28)  
Inventories         0 235  
Other current assets         487 216  
Other assets         54 257  
Accounts payable and accrued expenses         371 108  
Deferred revenues         0 29  
Other long-term liabilities         0 54  
Net cash used in operating activities         (2,911) (4,420)  
Cash flows provided by (used in) investing activities:              
Purchases of property and equipment         (23) (6)  
In process research and development acquired from NanoTx Therapeutics         (400) 0  
Proceeds from sale of business         0 5,637  
Net cash provided by (used in) investing activities         (423) 5,631  
Cash flows used in financing activities:              
Principal payments of long-term obligations         (5,307) (3,490)  
Payment of financing lease liability (33)   (20)   (51) (28)  
Proceeds from exercise of warrants         366 0  
Proceeds from sale of common stock, net         0 1,984  
Net cash used in financing activities         (4,992) (1,534)  
Effect of exchange rate changes on cash and cash equivalents         0 (4)  
Net decrease in cash and cash equivalents         (8,326) (327)  
Cash, cash equivalents, and restricted cash at beginning of period   $ 17,592   $ 5,301 17,592 5,301 $ 5,301
Cash, cash equivalents, and restricted cash at end of period $ 9,266   $ 4,974   9,266 4,974 $ 17,592
Cash paid during period for:              
Interest         372 826  
Supplemental schedule of non-cash investing and financing activities:              
Common stock issued in payment for in process research and development         $ 381 $ 0